Surgical Resection of Pulmonary Metastasis from Renal Cell Carcinoma

Kim, Jae Jun; Park, Jae-Kil; Wang, Young-Pil

doi:10.5090/kjtcs.2011.44.2.159

“…It is important to satisfy the dual goals of complete resection and impacting pulmonary function as little as possible. Lobectomy and pneumonectomy have been safely performed for multiple pulmonary metastasis in cases of other types of primary cancer [22][23][24][25][26][27] . In cases of 2-4 lesions with potential R0 resectability, surgery is reportedly justified in colorectal cancer [28][29][30] .…”

Section: Discussionmentioning

confidence: 99%

Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma

Yamashita

¹

,

Miyamoto

²

,

Hama

³

et al. 2015

View full text Add to dashboard Cite

Aim: This study aimed at investigating the survival impact of pancreatic ductal adenocarcinoma (PDAC) recurrence as pulmonary metastasis. Methods: We performed a retrospective case-control study of 142 patients who underwent curative resection for PDAC at our institution between 2003 and 2012. Clinicopathological features were compared among patients stratified according to the recurrence pattern and pulmonary metastasis treatment strategy. Results: Patients underwent pancreaticoduodenectomy (n = 96), distal (n = 42), or total pancreatectomy (n = 4). At the last follow-up, 99 patients had developed recurrent post-resection PDAC, including 14 cases of isolated pulmonary recurrence. The median overall survival was significantly longer for patients with isolated pulmonary recurrence (40.3 months) than with other metastases (20.9 months; HR 5.85; p = 0.0156). Two patients underwent resection for isolated pulmonary recurrence, and both survived for ∼70 months after primary resection. Conclusion: Patients with first recurrence of PDAC as pulmonary metastasis had a better prognosis than patients with other types of metastases. Moreover, when isolated pulmonary metastasis is controlled for a certain period, pulmonary resection is likely to improve patient survival.

show abstract

“…Considering the renal cell carcinoma, it was reported that 5-years survival rates are between 21% and 60% after pulmonary metastasectomy [2][3][4][5][6][7][8]. It was also shown that metastasectomy would have an additional contribution to prognosis, especially in patients with few and small metastases and longer DFI [5][6][7][8][9].…”

Section: Discussionmentioning

confidence: 99%

Pulmonary metastases in urogenital cancers: Surgical treatment and outcomes

Ceylan

¹

,

Batıhan

²

,

Kaya

³

2023

Cirugía Española

0

View full text Add to dashboard Cite

Background Metastasis is remaining one of the major problems in cancer treatment. Like many other malignancies, urogenital tumors originating from kidney, prostate, testes, and bladder tend to metastasize to the lungs.The aim of this retrospective study is to evaluate the results of pulmonary metastasectomy in patients with primary urogenital tumors. Methods This study was approved by the local ethical committee. This study retrospectively analyses the patients who underwent lung resections for metastases in our department between 2002 and 2018. 22 out of 126 patients referred for pulmonary metastasectomy to our department had metastases from urogenital tumors. Demographic data and clinicopathological features were extracted from the medical records. Diseasefree interval (DFI) was de ned as the time between the rst curative surgery and the detection of pulmonary metastasis.Results Among 22 patients who underwent lung metastasectomy consisted of 17 males and ve females. Their metastasis originated from renal cell carcinoma (RCC; n = 9), bladder tumor (n = 7), testis tumors (n = 4), and prostate cancer (n = 2). There was no intraoperative complication. Postoperative complications were seen in 2 patients.Conclusions Although pulmonary metastases and its surgical management in various types of tumors is well known and documented, the data is limited to the role of the surgery for metastases of urogenital cancers on literature. Despite the limitations of this study, we aim to document our promising results of pulmonary metastasectomy in patients with primary urogenital tumors.Trial registration This study was approved by the local ethical committee (Registration number: 49109414-604.02 ; Date: 11/06/2019).or retroperitoneum was described as a negative predictive factor of disease-free survival. ** The number of cases undergoing pulmonary metastasectomy for prostate cancer is very limited in the literature therefore, we reviewed 2 well written case report. *** 6 months survival was reported as 100% for urologic cancers and 94.44% for genital cancers.

show abstract

“…Considering the renal cell carcinoma, it was reported that 5-years survival rates are between 21% and 60% after pulmonary metastasectomy [2][3][4][5][6][7][8]. It was also shown that metastasectomy would have an additional contribution to prognosis, especially in patients with few and small metastases and longer DFI [5][6][7][8][9].…”

Section: Discussionmentioning

confidence: 99%

Pulmonary metastases in urogenital cancers; surgical treatment and outcomes

Ceylan¹,

Batıhan²,

Kaya³

2019

Thoracic Surgery

0

View full text Add to dashboard Cite

Background Metastasis is remaining one of the major problems in cancer treatment. Like many other malignancies, urogenital tumors originating from kidney, prostate, testes, and bladder tend to metastasize to the lungs. The aim of this retrospective study is to evaluate the results of pulmonary metastasectomy in patients with primary urogenital tumors. Methods This study was approved by the local ethical committee. This study retrospectively analyses the patients who underwent lung resections for metastases in our department between 2002 and 2018. 22 out of 126 patients referred for pulmonary metastasectomy to our department had metastases from urogenital tumors. or retroperitoneum was described as a negative predictive factor of disease-free survival. ** The number of cases undergoing pulmonary metastasectomy for prostate cancer is very limited in the literature therefore, we reviewed 2 well written case report. *** 6 months survival was reported as 100% for urologic cancers and 94.44% for genital cancers.

show abstract

Surgical Resection of Pulmonary Metastasis from Renal Cell Carcinoma

Cited by 11 publications

References 15 publications

Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma

Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma

Pulmonary metastases in urogenital cancers: Surgical treatment and outcomes

Pulmonary metastases in urogenital cancers; surgical treatment and outcomes

Contact Info

Product

Resources

About